Connect with us

Press Release

ADAMoracle—The First Decentralized Oracle That Supports Wide-area Node Quotation

Published

on

The birth of ADAMoracle

In the blockchain system, there are underlying service providers that provide vital nutrition to the main system, but are not easily noticed by the public, which is oracle. As a middleware connecting the blockchain system and real-world data, the oracle is a bridge that connects outside data with blockchain world and realizes the exchange of data and information .

With the large-scale application of blockchain technology in recent years, DeFi, NFT and other fields have shown a blowout development, and the market’s demand and requirements for underlying services are also constantly improving. However, the current major oracle products are still largely opaque, inaccurate, difficult to expand, and poorly resistant to attacks. Oracles that can truly meet market demand in an all-round way are extremely scarce.

Our Background Advantage

In order to meet the growing demand of the market, in July 2020, the ADAMoracle laboratory was officially established in the Emirate of Dubai, led by Ahmed Ebrahim, the founder and CEO of ADAMoracle, and the team led by CMO Christopher Quet and COO Olga Petrovska set out to create brilliant oracle products .

ADAMoracle has been favored by a large number of capital and institutions at the beginning of the establishment of the project. So far, ADAMoracle has obtained Collinstar, Redline Capital, CoinBene Labs, BTXCapital, 7O’Clock Foundation, MCS Capital, ChainUP Capital, ZB Labs ,Chain Capital and other dozens of institutions have strategic investment of USD 2 million.

ADAMoracle builds Web3.0 distributed wide-area node computing oracle network

In the Web3.0 blockchain network era, a complete middle-tier infrastructure will promote the next stage of the growth engine of the blockchain. However, the performance of the oracle network currently on the market and the cumbersomeness of building applications have discouraged many DeFi DApps. ADAMoracle is committed to changing the current status quo and completing a truly decentralized oracle network.

Web 3.0 developers can use ADAMoracle to implement a decentralized computing network with cross-chain support for multi-node computing. For the DeFi application market, customers connect to ADAMoracle through smart contracts to obtain prices, and obtain more accurate and secure quotations through multi-node connection quotations. At the same time, data is automatically distributed and stored. Each price feed will better verify the degree of decentralization, data accuracy, stronger stability and safety, and scalability of ADAMoracle.

Major features of ADAMoracle system

High security: ADAMoracle avoids a single point of failure by connecting multiple nodes to calculate and verify the quotation; the both way quotation and price verification prevent ADAMoracle from related attacks and further losses to customers;

Decentralization (high participation): ADAMoracle can connect to multiple types of servers through the global node to become bidders and verifiers, and participate in the oracle price generation. Many members can participate in the future development route of ADAMoracle;

High scalability: ADAMoracle supports more cross-chain DeFi DApps applications based on Polkadot, OKExChain, and BSC, compatible with many blockchain technology development frameworks, and builds a Defi application ecosystem in a friendly collaboration with developers;

High accuracy: with an oracle performance evaluation system, the deviation between the quotation per minute and the market price is accurate to 0.0012, it is very accuracy quotation system.

Low threshold: ADAMoracle can be connected to multiple types of servers, which greatly reduces maintenance and operation costs and achieves a quotation system platform that everyone can participate in.

The operation flow of ADAMoracle is as shown in the figure above. Customer release request–ADAMOracle Saas System releases the request contract after receiving it–System picking up nodes–Wide area node quotation–Aggregation of data provided by wide area node data providers–receving accurate Results–feedback to customers.

This process includes the three roles of data aggregator, node computing provider, and storage service provider in the ADAMoracle operation flow.

ADAMoracle data aggregator:

Data aggregators obtain key data from multiple exchanges (for example: OKEx, Coinbase, Huobi, Binance, etc.), and transmit the most reliable data to the ecosystem, thereby providing safe and reliable prices for the DeFi protocol Data, truly realize the decentralization of ADAMoracle data source and ensure the openness and transparency of data;

Node Computing provider:

As the first decentralized oracle that supports wide-area node quotation, the data service on the ADAMoracle chain has the advantage of high security and low threshold. The ADAMoracle has created a grand node service network, which can accommodate thousands of service providers for data verification and quotation services at the same time, which not only ensures the accuracy and credibility of the data, but also improves the anti-attack of the oracle itself. Lower the threshold for participation. Any enterprise or individual that has certain basic server equipment, has certain technical operation and maintenance capabilities, and can start nodes to complete Docker images, can join the ADAMoracle ecosystem and share the token ADAM dividend.

ADAMoracle has 33 global nodes and 66 backup nodes worldwide, and the global node can create its own mining pool in the future to connect thousands of multiple types of servers for secure distributed quotation, and the distributed quotation system is effective, This avoids the occurrence of a single point of failure, and provides a safer and more reliable quotation service for corporate customers.

Storage Service Provider

ADAMoracle not only implements a wide-area distributed quotation system under the multi-node computing network, but also securely distributes the generated on-chain/off-chain data to the blockchain storage system to prevent data loss. The decentralized oracle network is committed to the fact that every mining machine can become a offerer and verifier, participate in the oracle price quotation, and jointly govern and decide the future development route of ADAMoracle.

Summary:The ADAMoracle wide-area node computing network oracle architecture realizes unbounded interstellar network computing, so that each multi-type server can realize automated quotation, and has a safe rating function to ensure the accuracy of the price and better guarantee the oracle. The network’s decentralization characteristics and availability performance make it possible to have both fish and bear’s paws. ADAMoracle will attract more excellent developers to create excellent DeFi DApps applications. These new business paradigms of Web3.0 will also become a new form of economic society and organization in the future.

Our Economic Advantages

ADAMoracle for sustainable long-term development

Different from Bitcoin, ADAMoracle is not only a “green project” with decentralized energy resources, but also an infrastructure service facility that serves the majority of DeFi ecological projects. That is to say, the value of the ADAMoracle is not limited to the consensus of its own users. It will also generate actual value as the industry grows and develops. In the future, the ADAMoracle will support OKExchain, ETH, BSC, HECO, Polkadot and other public chains to further expand the ecology and promote the development of rich business formats such as lending, asset synthesis, and prediction markets.

ADAMoracle is a project that seeks long-term and stable development. It is based on the DeFi ecosystem, focuses on the entire blockchain system, and focuses on providing smart contract developers with comprehensive tools and data. ADAM is ADAMoracle’s contribution reward token to participants. It is the core value of the ecosystem. Its value comes from the value contribution of ecological members. The total issuance of ADAM is 100 million.

There are several ways to obtain ADAM tokens:

1. Participate in mining to obtain

50% of ADAM tokens are produced by mining, which is one of the main ways to obtain ADAM. Users can obtain ADAM token rewards by participating in pledge or liquidity mining;

2. Participate the ADAMoracle architecture

At present, the ADAMoracle has officially started the recruitment of global nodes, and many storage nodes will be recruited in the future. As a member of the ADAMoracle ecosystem, you can not only share the ADAMoracle development dividends, but also share the handling fees paid by the data demander. Currently, many Dapp projects have rigid data requirements. When they issue data requests to the ADAMoracle oracle machine, they need to pay ADAM as a handling fee. The node computing provider can obtain the corresponding ADAM by providing accurate quotation for the data demander; Aggregators and storage service providers can also get a corresponding share.

3.Participate to build up ADAMoracle ecological

ADAMoracle is a project that adopts decentralized community voting governance. The higher the value contribution of ecological members, the more ADAM token incentives will be obtained.

In the future, we will also establish “ADAMoracle Labs”, aiming to establish an open decentralized financial ecosystem based on the oracle protocol, and use the advantages of encrypted economic incentives to obtain and verify data. Allow the majority of ecological participants to better participate in our ecological construction, expand ecological application scenarios, form an ecological closed loop, and share and use financial digital asset data.

In general, the ADAMoracle creates a continuous positive incentive. The more users there are, the more fees will be generated; the more ecological participants, the higher the value of ADAM itself. At the same time, the increase in the value of ADAM is more conducive to the adoption of ADAMoracle oracles. Like Bitcoin, miners will compete to dig blocks for Token rewards to form a virtuous circle.

Looking around at the current high-quality oracle projects in the market, there are not a few that have a market value of over 100 million US dollars. Behind the prosperity that the total market value of cryptocurrencies exceeded US$2.5 trillion, there are countless groups who have quietly dedicated themselves to them. They do not take the model hotspot as a paradigm, but are rooted in the most basic field of the industry and empower the industry to flourish. They will never Forgotten by people.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Neuralia TMS Breaks Down TMS Therapy Cost and Insurance Options

Published

on

Australia, 20th Nov 2026 – Neuralia TMS, a specialist provider of transcranial magnetic stimulation (TMS) in Perth, Western Australia, has announced a plain breakdown of how funding works for patients considering TMS therapy, covering Medicare, referrals and private health insurance. According to the company, the explanation sets out which parts of a course are funded, which are not, and where patients are asked to confirm their circumstances before booking.

Neuralia TMS provides a non-invasive form of brain stimulation (link pending) in a specialised TMS suite, the company said. TMS uses an electromagnetic coil placed against the scalp to deliver magnetic pulses, and treatment is arranged as a course of sessions rather than a single visit. The company also offers transcranial direct current stimulation, known as tDCS, and pharmacogenetic testing, with clinics in Como, Kardinya and Armadale.

What the Announcement Means for Medicare Patients

Medicare is Australia’s public health insurance scheme, and some services attract a Medicare rebate when set criteria are met. According to Neuralia TMS, most patients on an initial Medicare-funded course pay $0 out of pocket for TMS at the clinic. The company states that Medicare covers up to 35 sessions in an initial course, and that a course is typically delivered five times a week over four to six weeks.

“Patients should be able to see what Medicare funds and what it does not before they book,” said Dr Shanek Wick, Medical Director of Neuralia TMS. “Eligibility depends on each person’s history, which is why the clinic asks patients to check their circumstances with the team.”

The company also states that a rebate applies only when every eligibility requirement is met. Previous TMS in any setting rules out the initial-course Medicare item, Neuralia TMS said, and an earlier course of treatment on its own does not show that a patient qualifies for a rebate. Patients are asked to contact the clinic about their circumstances, and the company refers them to a separate article on Medicare coverage for the full criteria.

How Referrals, Retreatment and Maintenance Work in Practice

A referral from a general practitioner or psychiatrist starts the Medicare eligibility process, although a referral does not establish eligibility by itself. Neuralia TMS says general practitioners can refer patients by Healthlink, fax or email using a standard referral letter, or through a secure online form. A team member then contacts the patient to book the first appointment. The team reviews the patient’s medical history and consults the referring practitioner before a treatment plan is prepared.

Separate arrangements apply to further treatment. Up to 15 retreatment sessions may be covered if needed, starting four months after the initial course, the company said, provided the criteria are met. Stand-alone maintenance TMS outside the initial and retreatment courses is not funded under the Medicare items, according to Neuralia TMS.

Patients who are not eligible for Medicare are directed to ask the clinic about their circumstances before booking. Enquiries from the Department of Veterans’ Affairs community are directed to a dedicated DVA cost resource or to the clinic team.

What Private Health Insurance May and May Not Cover

On private cover, the company says that private health insurance rarely covers the psychiatrist’s professional fees for TMS sessions delivered in a community setting. It advises patients to check with their insurer about those fees before starting treatment. Insurers set their own policy terms, and cover differs between funds and between levels of cover, so the company’s guidance is to confirm the details directly with the insurer rather than assume that a policy applies.

The statements in this release describe the arrangements as Neuralia TMS sets them out, and they do not amount to a promise of coverage for any individual patient. The company said that questions about funding can be put to the clinic by email before an appointment is made.

Looking Ahead

Neuralia TMS said the funding information is intended as a starting point, and that each patient’s position is confirmed individually once a referral has been received and the clinic has reviewed it.

“Clear funding information matters because the rules apply differently to each person, and the aim is for every patient to understand their position before treatment begins,” said Dr Wick. “Patients with questions are welcome to contact the clinic, and the team will go through their circumstances.”

About Neuralia TMS

Neuralia TMS is a Perth based provider of transcranial magnetic stimulation. The company also offers tDCS and pharmacogenetic testing, and its medical director is Dr Shanek Wick, a specialist psychiatrist.

For additional information about TMS therapy cost and related mental health service developments, contact Neuralia TMS by email at info@neuralia.com.au or call 1 6230 3996. The clinic is located at Unit 2A/125 Melville Parade, Marview House, Como, WA 6152.

Media Contact

Organization: Neuralia TMS (Como)

Contact Person: Dr Shanek Wick

Website: https://www.neuraliatms.com.au/

Email: Send Email

Contact Number: +6162303996

Address: Unit 2A/125 Melville Parade

Address 2: Marview House, Como WA 6152

Country: Australia

Release id: 50971

View source version on King Newswire:
Neuralia TMS Breaks Down TMS Therapy Cost and Insurance Options

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Precision Medicine Emerges as a Major Focus for Healthcare Innovation in 2027

Published

on

Amsterdam, Netherlands, 20th Nov 2026 – The global life sciences landscape is undergoing a structured realignment as precision medicine establishes itself as a foundational pillar of biopharmaceutical research and therapeutic development. Historically, pharmaceutical methodologies relied predominantly on broad-population models, applying standardized therapeutic interventions across heterogeneous patient cohorts. However, advances in high-throughput genomic sequencing, molecular profiling, and computational biology have fundamentally transformed this paradigm. Modern drug development strategies increasingly prioritize targeted mechanisms of action informed by distinct biological markers and individual genetic variations. As research institutions and commercial developers direct resources toward stratified medicine, the sector is witnessing a systemic shift toward therapeutic frameworks designed around biological specificity and diagnostic validation. This strategic transition reflects a broader recognition that clinical variance can be addressed through disciplined molecular characterization rather than generalized intervention models.

Precision Medicine Emerges as a Major Focus for Healthcare Innovation in 2027

Within this evolving environment, revueltobio focuses its analytical and scientific efforts on the strategic intersection of molecular biology, pharmaceutical research, and computational methodologies. The identification of novel therapeutic targets now depends heavily on the capacity to process intricate biological datasets, decipher complex cellular signaling networks, and evaluate patient stratification criteria at earlier stages of development. By concentrating on the scientific concepts underpinning personalized therapeutic interventions, revuelto365 engages with the foundational questions that govern how targeted therapies move from initial conceptualization toward practical application in modern healthcare environments. In doing so, the organization prioritizes structural frameworks that align mechanistic research with translational potential across distinct disease profiles.

A critical dimension of this scientific transition is the growing reliance on advanced computational tools to enhance traditional laboratory workflows. The integration of artificial intelligence and machine learning within preclinical exploration has enabled research teams to analyze macromolecular structures, predict pharmacokinetic behaviors, and screen chemical libraries with higher analytical fidelity. In tracking these methodologies, revueltobio examines how computational biology can be systematically harmonized with empirical biological research to reduce timelines and resource expenditure in discovery programs. Through initiatives such as revuelto365, the organization assesses ongoing developments across analytical chemistry, biocomputing, and molecular modeling, tracking how these technologies contribute to more targeted, reliable scientific outcomes. The objective remains focused on evaluating computational models that can reliably reflect biological complexity without losing fidelity during empirical testing.

The implementation of precision healthcare frameworks also requires rigorous attention to diagnostic infrastructure and biomarker discovery. Therapeutic efficacy in stratified patient populations is intrinsically linked to the availability of robust diagnostic tools capable of identifying cellular anomalies, genetic predispositions, and disease-specific protein signatures. As biopharmaceutical organizations explore novel intervention pathways, understanding the interplay between genetic profiling and molecular mechanisms becomes paramount. revueltobio directs significant attention to these interdependencies, analyzing how continuous developments in molecular diagnostics and biomarker validation inform modern therapeutic design across diverse therapeutic areas, including oncology, immunology, and metabolic conditions. This analytical focus underscores the necessity of establishing clear correlations between measurable biological indicators and clinically relevant endpoints.

Furthermore, the translation of theoretical biology into functional therapeutic platforms presents significant methodological challenges that require rigorous evaluation. Preclinical validation pathways demand extensive characterization of pharmacokinetic and pharmacodynamic interactions, target engagement kinetics, and potential off-target effects. By evaluating the methodologies used to address these analytical hurdles, revueltobio highlights the critical importance of standardization across assay systems and experimental designs. Establishing reproducible experimental paradigms is essential to ensuring that therapeutic hypotheses are supported by robust biological evidence prior to downstream progression.

Looking toward the broader trajectory of healthcare and biotechnology, the sustained adoption of precision medicine depends on responsible innovation and a clear understanding of translational research requirements. The convergence of digital infrastructure, molecular biology, and pharmaceutical science presents complex scientific and operational questions that demand disciplined evaluation. revueltobio maintains a prospective orientation within the life sciences ecosystem, emphasizing scientific integrity, methodological rigor, and the careful examination of emerging technological frameworks that support the ongoing evolution of global healthcare. Through systematic observation of both computational developments and biological research paradigms, the entity continues to explore the principles shaping modern biopharmaceutical strategy.

What is revueltobio?

revueltobio is a biotechnology and life sciences entity focused on the exploration of pharmaceutical research, molecular biology, and technological methodologies that influence modern therapeutic discovery and precision medicine. The organization examines industry trajectories and research principles to better understand how scientific tools inform modern healthcare frameworks.

What areas of scientific research does revueltobio focus on?

revueltobio concentrates on several interconnected domains within the life sciences, including pharmaceutical discovery approaches, molecular biology, biomarker-driven precision medicine, and the application of advanced computational tools in biological research. Its work emphasizes the points of intersection between experimental biology and analytical infrastructure.

How does revueltobio approach precision medicine?

revueltobio views precision medicine as a crucial model for future healthcare delivery, focusing on how genomics, molecular biomarkers, and tailored diagnostic approaches enable more targeted and effective therapeutic strategies. This approach centers on moving away from generalized population treatment paradigms toward stratified biological models.

Does revueltobio incorporate computational biology and artificial intelligence into its framework?

revueltobio examines the utility of artificial intelligence, machine learning, and computational modeling as analytical tools designed to optimize biological data interpretation and support early-stage pharmaceutical discovery concepts. The focus is on evaluating how digital tools complement laboratory experimentation.

How does revueltobio view the role of biomarkers in modern drug development?

revueltobio recognizes biomarkers as vital components of modern translational medicine, essential for patient stratification, measuring biological responses, and validating targeted therapeutic mechanisms throughout the research process.

What is the primary mission guiding revueltobio?

The mission of revueltobio is to support scientific advancement by exploring innovative approaches in biotechnology and pharmaceutical research, grounded in scientific integrity and responsible technological integration. The organization seeks to clarify the concepts driving precision therapeutics.

How does revueltobio assess emerging biotechnology trends?

revueltobio evaluates emerging biotechnology trends through structured scientific analysis, monitoring technical developments in molecular diagnostics, computational life sciences, and therapeutic discovery frameworks to gauge their viability in translational research.

Is revueltobio focused on specific therapeutic categories?

revueltobio maintains a broad analytical perspective that spans multiple therapeutic fields where precision methodologies, molecular profiling, and targeted drug discovery frameworks are actively evolving, including oncology, immunology, and metabolic conditions.

Where can individuals learn more about revueltobio and its initiatives?

Information regarding revueltobio, its focus areas, and its perspectives on life sciences innovation is available through the organization’s official digital channels and publications, where it shares analytical insights into biotechnology developments.

About revueltobio

RevueltoBio – Advancing Biotechnology and Pharmaceutical Innovation

revuelto365 is a biotechnology and life sciences company focused on exploring the future of pharmaceutical research, drug discovery, and healthcare innovation. Through a science-driven approach, we aim to contribute to the advancement of modern medicine by bringing together emerging technologies, scientific knowledge, and innovative research concepts.

Our areas of interest span pharmaceutical development, molecular biology, biotechnology, precision medicine, and next-generation therapeutic technologies. We recognize the growing importance of artificial intelligence, computational biology, and advanced analytical methods in shaping the future of drug discovery and pharmaceutical research.

Our Mission

Our mission is to support scientific progress by exploring innovative approaches to pharmaceutical research and biotechnology. We believe that responsible innovation, scientific integrity, and technological advancement are essential to addressing the evolving challenges of global healthcare.

Our Vision

Our vision is a future in which biotechnology and pharmaceutical innovation contribute to more precise, efficient, and accessible healthcare solutions worldwide.

Our Areas of Focus

– Pharmaceutical Research: Exploring scientific approaches and emerging technologies relevant to modern drug discovery and development. – Biotechnology Innovation: Examining advances in molecular biology, biological sciences, and next-generation therapeutic technologies. – Precision Medicine: Supporting awareness of personalized healthcare approaches informed by genetics, biomarkers, and advanced diagnostics. – Artificial Intelligence in Healthcare: Exploring the potential of AI, machine learning, and computational technologies in pharmaceutical research. – Life Sciences: Following scientific developments that may shape the future of medicine, biotechnology, and global healthcare.

Looking Toward the Future

As biotechnology continues to evolve, RevueltoBio is committed to a forward-looking perspective that emphasizes scientific knowledge, responsible innovation, and the potential of emerging technologies.

We believe the future of healthcare will be shaped by the convergence of biological sciences, advanced computing, and pharmaceutical innovation.

RevueltoBio — Exploring Science. Advancing Possibilities.

Media Contact

Organization: revueltobio

Contact Person: Daniel Vermeer

Website: https://revueltobio.com

Email: Send Email

Address: 123 Science Park

City: Amsterdam

Country: Netherlands

Release id: 50976

View source version on King Newswire:
Precision Medicine Emerges as a Major Focus for Healthcare Innovation in 2027

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

NiobiumX Mining Inc. (OTCQB: NIOXF): Niobium Is Behind US Missiles and Next-Generation AI Chips. The US Imports All of It.

Published

on

Toronto, Canada, November 20th, 2026, FinanceWire

  • Alphabet, Amazon, Microsoft and Meta plan more than $700 billion of 2026 capital spending, Sherwood News reported; SIPRI put 2025 world military spending at a record $2.887 trillion.
  • Niobium goes into jet engines and rockets, the Royal Society of Chemistry says. The US has not mined it since 1959, according to the USGS.
  • NiobiumX Mining Inc. (OTC: NIOXF), an early-stage explorer with no resource estimate, holds claims in Quebec beside Niobec, North America’s only producing niobium mine.

Alphabet, Amazon, Microsoft and Meta plan to spend more than $700 billion on capital expenditures in 2026, Sherwood News reported. Amazon alone expects about $220 billion, CEO Andy Jassy said in July.

Military budgets set their own record. World military spending reached $2.887 trillion in 2025, the 11th consecutive annual rise, according to SIPRI.

Those are the budgets behind two familiar groups of shares, defense stocks and AI infrastructure stocks. One metal appears on both sides of the ledger.

NiobiumX (OTC: NIOXF) holds ground beside the only producing niobium mine in North America. Proximity to that mine is not necessarily indicative of mineralization on NiobiumX’s property. See the “Adjacent Properties” disclaimer on the Campaign Disclosure page linked below. The company is an early-stage explorer, and it holds no interest in that mine, Niobec.

Niobium has established defense applications and emerging applications in AI computing. It is one of the critical minerals behind America’s weapons and the next generation of AI computing, used in the jet engines, rocket motors and missiles of the US military and in the superconducting circuits being developed to cut AI’s power and heat. The US produces none of it: according to the US Geological Survey, America has not mined niobium since 1959 and imports all of it.

Defense stocks and the niobium alloy inside jet and rocket engines 

On the defense side, niobium goes into heat-resistant alloys. Inconel 718, a superalloy used in aircraft and land-based gas turbine engines and liquid-fuelled rockets, contains 4.75% to 5.50% niobium plus tantalum, according to maker Special Metals. CSIS calls niobium “indispensable for critical components in hypersonic vehicles.”

Separately, the Congressional Budget Office estimated in September that the US had used between one-half and two-thirds of its stock of certain interceptors, among them Patriot, THAAD, SM-3 and SM-6. Rebuilding could take at least five years, Defense News reported on the CBO estimate. These figures do not indicate the niobium content of these interceptors.

In the US, steels take about 77% of niobium use and superalloys about 23%, the USGS says.

AI stocks and the niobium compound in next-generation chips 

Electricity demand from data centers rose 17% in 2025, against 3% growth in global demand, the International Energy Agency says. The agency projects data-center electricity use will roughly double, from 485 terawatt-hours in 2025 to 950 in 2030.

On September 7, 2026, the research institute imec reported circuits built on niobium titanium nitride using standard 300 mm wafers. imec says superconducting technology has the potential to outperform state-of-the-art CMOS by 100 times in energy efficiency. That figure is imec’s estimate, and superconducting computing remains at the research and early development stage. Its program targets “foundries, hyperscalers and system companies.”

Which country is the largest producer of niobium?

Brazil. It accounts for about 93% of global production and Canada about 5%, according to the US Geological Survey’s 2026 niobium data. US imports are worth about $525 million a year.

Ownership matters for anyone researching niobium stocks. CBMM, which CSIS says controls three-quarters of Brazil’s output, is privately held. Niobec in Quebec, the only primary niobium producer outside Brazil according to its owner, has been private since 2015. A Nebraska project is developing what would be the only US niobium mine, but it is not producing, the USGS says.

NIOXF: the Quebec claims beside North America’s only niobium mine 

NiobiumX’s Shipshaw Property comprises 48 mineral claims totalling about 2,686 hectares in the Saguenay region of Quebec, the company says. It also says its nearest claim boundary lies less than 2 km from Niobec’s mining-lease boundary. Proximity to Niobec is not necessarily indicative of mineralization on the Shipshaw Property. See the “Adjacent Properties” disclaimer on the Campaign Disclosure page linked below. The Shipshaw carbonatite is one of five carbonatite intrusions in the Waswanipi-Saguenay zone that Géologie Québec selected for characterization in a 2024 metallogenic bulletin, according to the company. Selection for characterization does not establish the presence of niobium mineralization.

Shipshaw has no resource estimate, and proximity to a producing mine does not mean similar mineralization. Its next steps are set out in the company’s October exploration update, and company information is at niobiumx.com.

About Us

NiobiumX Mining Inc. is a Canadian mineral exploration company focused on niobium and rare earth elements. The Company’s principal asset is the Shipshaw Property, a package of 48 mineral claims totalling approximately 2,686 hectares in the Saguenay region of Québec, situated within the Saguenay Graben of the Grenville Geological Province. The Shipshaw carbonatite is one of five carbonatite intrusions in the Waswanipi-Saguenay zone selected for characterization by Géologie Québec in metallogenic bulletin BM 2024-02. The Company has no current mineral resource or reserve estimate on the property. Niobium is designated a critical mineral by Canada, the United States, the European Union and Australia.

Key facts

  • Alphabet, Amazon, Microsoft and Meta 2026 capital spending plans: more than $700 billion (Sherwood News)
  • Amazon’s expected 2026 capital spending: about $220 billion (CEO Andy Jassy)
  • World military spending, 2025: a record $2.887 trillion (SIPRI)
  • US niobium imports: about $525 million a year (USGS)
  • US niobium end use: steels about 77%, superalloys about 23% (USGS)
  • Shipshaw Property: 48 claims, about 2,686 hectares (NiobiumX)

Campaign Disclosure

Click here to read the full NiobiumX Mining Inc. campaign disclosure, including details regarding the publisher’s compensation, conflicts of interest, and other important disclaimers relating to these materials.

Contact

President
Kirby Renton
NiobiumX Mining Inc.
contact@niobiumx.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST